Literature DB >> 31269334

Immunohistochemical assessment of metalloproteinases MMP2 and MMP9 expression in canine various subtypes of lymphomas in relation with proliferative and apoptotic markers.

J Sokołowska1, K Urbańska1.   

Abstract

Matrix metalloproteinases 2 and 9 (MMP2 and MMP9) are proteolytic enzymes involved with extracellular matrix degradation. They play a role in tumor invasion and metastases. Because of their ability to degrade signaling molecules presented in extracellular matrix, MMPs contribute to tumor proliferation and apoptosis. The aim of this study was to evaluate expression of MMP2 (latent and both active and latent forms) and MMP9 (active, latent, active and latent forms) in different subtypes of canine lymphomas and their relationship with proliferative (mitotic index and percentage of Ki67-positive cells) and apoptotic (apoptotic index) markers. Expression of MMPs was assessed immunohistochemically using an immunoreactive score system. Expression of both MMPs was found in all 20 examined lymphomas belonging to six subtypes. Most cases showed a moderate level of all analyzed forms of MMP2 and MMP9. High expression of MMPs was found in single cases. Except for a positive correlation between the active form of MMP9 and the mitotic index for all lymphoma cases, no other correlations between any remaining forms of MMPs and neither proliferative nor apoptotic markers were found, irrespective of whether the analysis encompassed all cases or the most numerous lymphoma subtypes i.e. centroblastic and Burkitt-like. Our results were not able to clearly confirm the influence of MMPs on the proliferation and apoptotic activity of canine lymphoma cells. However, further studies examining MMPs activity by zymography, expression of their inhibitors and other factors involved in activation of cell proliferation and apoptosis inhibition are needed to clarify the role of MMPs, especially the active form of MMP9, in the behavior of canine lymphoma cells. Copyright© by the Polish Academy of Sciences.

Entities:  

Keywords:  apoptotic markers; dog; immunolabelling; lymphoma; matrix metalloproteinases; proliferative markers

Year:  2019        PMID: 31269334     DOI: 10.24425/pjvs.2019.127087

Source DB:  PubMed          Journal:  Pol J Vet Sci        ISSN: 1505-1773            Impact factor:   0.821


  6 in total

1.  Overexpression of microRNA-367 inhibits angiogenesis in ovarian cancer by downregulating the expression of LPA1.

Authors:  Qingling Zheng; Xin Dai; Wei Fang; Yan Zheng; Jin Zhang; Yanxiang Liu; Donghua Gu
Journal:  Cancer Cell Int       Date:  2020-10-02       Impact factor: 5.722

2.  ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma.

Authors:  Tianbo Xu; Hailong Ruan; Su Gao; Jingchong Liu; Yuenan Liu; Zhengshuai Song; Qi Cao; Keshan Wang; Lin Bao; Di Liu; Junwei Tong; Jian Shi; Huageng Liang; Hongmei Yang; Ke Chen; Xiaoping Zhang
Journal:  Aging (Albany NY)       Date:  2020-01-30       Impact factor: 5.682

3.  Compared with High-intensity Interval Exercise, Moderate Intensity Constant Load Exercise is more effective in curbing the Growth and Metastasis of Lung Cancer.

Authors:  Zhe Ge; Shan Wu; Zhengtang Qi; Shuzhe Ding
Journal:  J Cancer       Date:  2022-02-28       Impact factor: 4.207

4.  microRNA-181a promotes the oncogene S100A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C.

Authors:  Y Wang; H Ye; Y Yang; J Li; A Cen; L Zhao
Journal:  J Endocrinol Invest       Date:  2021-06-18       Impact factor: 4.256

5.  LncRNA LINC00662 promotes colon cancer tumor growth and metastasis by competitively binding with miR-340-5p to regulate CLDN8/IL22 co-expression and activating ERK signaling pathway.

Authors:  Bo Cheng; Aimei Rong; Quanbo Zhou; Wenlu Li
Journal:  J Exp Clin Cancer Res       Date:  2020-01-03

6.  Overexpression of HOXD8 inhibits the proliferation, migration and invasion of breast cancer cells by downregulating ILP2 expression.

Authors:  Xiaoyun Wen; Yu Chen; Xiansong Fang
Journal:  Exp Ther Med       Date:  2021-07-15       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.